The genetics of the p53 pathway, apoptosis and cancer therapy - PubMed (original) (raw)
Review
doi: 10.1038/nrd2656.
Affiliations
- PMID: 19043449
- DOI: 10.1038/nrd2656
Review
The genetics of the p53 pathway, apoptosis and cancer therapy
Alexei Vazquez et al. Nat Rev Drug Discov. 2008 Dec.
Abstract
The p53 pathway has been shown to mediate cellular stress responses; p53 can initiate DNA repair, cell-cycle arrest, senescence and, importantly, apoptosis. These responses have been implicated in an individual's ability to suppress tumour formation and to respond to many types of cancer therapy. Here we focus on how best to use knowledge of this pathway to tailor current therapies and develop novel ones. Studies of the genetics of p53 pathway components - in particular p53 itself and its negative regulator MDM2 - in cancer cells has proven useful in the development of targeted therapies. Furthermore, inherited single nucleotide polymorphisms in p53 pathway genes could serve a similar purpose.
Similar articles
- Current strategies to target p53 in cancer.
Chen F, Wang W, El-Deiry WS. Chen F, et al. Biochem Pharmacol. 2010 Sep 1;80(5):724-30. doi: 10.1016/j.bcp.2010.04.031. Epub 2010 May 5. Biochem Pharmacol. 2010. PMID: 20450892 Review. - [P53 mutations, asset or disadvantage for cancer chemotherapy].
Jacquemin-Sablon A. Jacquemin-Sablon A. Bull Cancer. 1997 Jul;84(7):741-6. Bull Cancer. 1997. PMID: 9339201 Review. French. - p53 and response to chemotherapy and radiotherapy.
Ruley HE. Ruley HE. Important Adv Oncol. 1996:37-56. Important Adv Oncol. 1996. PMID: 8791127 Review. No abstract available. - Exploiting the p53 pathway for the diagnosis and therapy of human cancer.
Lane DP. Lane DP. Cold Spring Harb Symp Quant Biol. 2005;70:489-97. doi: 10.1101/sqb.2005.70.049. Cold Spring Harb Symp Quant Biol. 2005. PMID: 16869788 Review. - Death squads enlisted by the tumour suppressor p53.
Michalak E, Villunger A, Erlacher M, Strasser A. Michalak E, et al. Biochem Biophys Res Commun. 2005 Jun 10;331(3):786-98. doi: 10.1016/j.bbrc.2005.03.183. Biochem Biophys Res Commun. 2005. PMID: 15865934 Review.
Cited by
- Negative regulation-resistant p53 variant enhances oncolytic adenoviral gene therapy.
Koo T, Choi IK, Kim M, Lee JS, Oh E, Kim J, Yun CO. Koo T, et al. Hum Gene Ther. 2012 Jun;23(6):609-22. doi: 10.1089/hum.2011.114. Epub 2012 Feb 21. Hum Gene Ther. 2012. PMID: 22248367 Free PMC article. - Atg7 modulates p53 activity to regulate cell cycle and survival during metabolic stress.
Lee IH, Kawai Y, Fergusson MM, Rovira II, Bishop AJ, Motoyama N, Cao L, Finkel T. Lee IH, et al. Science. 2012 Apr 13;336(6078):225-8. doi: 10.1126/science.1218395. Science. 2012. PMID: 22499945 Free PMC article. - A structure-based virtual screening identifies a novel MDM2 antagonist in the activation of the p53 signaling and inhibition of tumor growth.
Hu QY, Li L, Li YH, Zhang HB, Deng T, Liu Y, Li FT, Xiao ZX, Cao Y. Hu QY, et al. Acta Pharmacol Sin. 2024 Oct 9. doi: 10.1038/s41401-024-01394-6. Online ahead of print. Acta Pharmacol Sin. 2024. PMID: 39384887 - Aciculatin induces p53-dependent apoptosis via MDM2 depletion in human cancer cells in vitro and in vivo.
Lai CY, Tsai AC, Chen MC, Chang LH, Sun HL, Chang YL, Chen CC, Teng CM, Pan SL. Lai CY, et al. PLoS One. 2012;7(8):e42192. doi: 10.1371/journal.pone.0042192. Epub 2012 Aug 13. PLoS One. 2012. PMID: 22912688 Free PMC article. - Gene-gene interactions in gastrointestinal cancer susceptibility.
Kim J, Yum S, Kang C, Kang SJ. Kim J, et al. Oncotarget. 2016 Oct 11;7(41):67612-67625. doi: 10.18632/oncotarget.11701. Oncotarget. 2016. PMID: 27588484 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous